

# Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment

Paul BIZIMANA (✉ [pbizimana2010@gmail.com](mailto:pbizimana2010@gmail.com))

Institut National de Santé Publique

Katja POLMAN

Institute of Tropical Medicine

Giuseppina ORTU

Global health consultant

Meryam KRIT

Institute of Tropical Medicine

Frédéric NSABIYUMVA

Université du Burundi

Audace NKESHIMANA

Institut National de Santé Publique

Ulrich BIJABUKA

Institut Universitaire des Sciences de la Santé et de Développement Communautaire

Marceline NIBAKIRE

Bureau de la Municipalité Sanitaire de Bujumbura

Jean-Pierre VAN GEERTRUYDEN

University of Antwerp

---

## Research

**Keywords:** Direct smear, Routine data, Health centre, Monitoring, Mass drug administration, Praziquantel, Schistosomiasis, Burundi

**Posted Date:** December 31st, 2019

**DOI:** <https://doi.org/10.21203/rs.2.19785/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Parasites & Vectors on April 21st, 2020. See the published version at <https://doi.org/10.1186/s13071-020-04076-4>.

# Abstract

## Background

Intestinal schistosomiasis is still a public health problem in Burundi. Since 2008, annual mass drug administration (MDA) with praziquantel have been rolled out in 11 endemic districts. The national programme relies on school based surveys with Kato-Katz (KK) to monitor the impact of MDA. We explored whether routine data on intestinal schistosomiasis as determined by direct fecal smears (DS) at health centre (HC) level could be used.

## Methods

We collected routine incidence data on intestinal schistosomiasis from the Burundian National Health Information System. These data concerned the number of intestinal schistosomiasis cases as detected by DS examination in the HC of all 45 sanitary districts (SD) between 2011 and 2015. A temporal trends analysis was performed using mixed Negative Binomial regression. Sanitary districts with MDA campaigns with praziquantel (n=11) were compared with those without (n=34). In addition, KK-based prevalence data from a school-based national mapping in 2014 were compared with the DS-based incidence data in the 45 SD.

## Results

In the 11 SD applying MDA with praziquantel, the incidence rate decreased significantly for the years 2014 ( $\beta_{2014}=-0.826$ ,  $p=0.010$ ) and 2015 ( $\beta_{2015}=-1.294$ ,  $p<0.001$ ) and for the five-year period ( $\beta=-0.286$ ,  $p<0.001$ ), whereas in the 34 districts without MDA, there was no significant trend ( $\beta=-0.087$ ,  $p=0.219$ ). In most of the 45 SD, the low prevalences based on KK in school children were confirmed by low incidence rates based on DS in the HC.

## Conclusions

The results of this preliminary study suggest that routine surveillance data at HC level, may be able to monitor the impact of MDA with praziquantel on intestinal schistosomiasis in Burundi. However, more sensitive POC diagnostic tests, such as the POC-CCA assay are desirable when moving from control to elimination of schistosomiasis. Elimination of intestinal schistosomiasis calls for integration of adequate diagnosis and treatment into routine activities of primary health care facilities.

## Background

Schistosomiasis is a parasitic disease caused by the genus *Schistosoma* [1,2]. It is one of the Neglected Tropical Diseases (NTD). Linked to poverty, schistosomiasis is more prevalent in countries and regions where hygienic conditions are precarious and access to safe water and adequate sanitation is limited [2]. Between 200 and 250 million of people in the world are infected [3], and 600-780 million are at risk [3,4].

The sub-Saharan Africa countries are the most affected by this disease, with more than 90% of the total burden [5,6].

In Burundi, intestinal schistosomiasis has been a public health challenge for many decades [7,8]. According to a nationwide school-based survey performed in 2007, based on the Kato-Katz (KK) test [9], 11 out of the 45 sanitary districts (SD) in Burundi were considered at risk of intestinal schistosomiasis. Since 2008, these 11 SD have been targeted for annual mass drug administration (MDA) with praziquantel (PZQ) to school-age children between five and 15 years old [9].

To measure the impact of MDA, epidemiological surveys using KK test were performed in a number of primary schools, chosen as sentinel sites [10]. These surveys demonstrated a decrease in *S. mansoni* infection from 12.7% in 2007 (baseline) to 1.1% in 2011 [10].

After six years of annual MDA in the targeted areas, a school-based national mapping was implemented to reassess the extent of the schistosomiasis problem, and to determine whether it was possible to move to the elimination phase [10]. The results from the KK test showed that there was a decline in the prevalence of infection, from 12.7% in 2007 (baseline) to 2.2% in 2014 [10].

Although the epidemiological surveys in sentinel sites and the national mapping provide a good estimation of the prevalence of schistosomiasis after several years of MDA, it is a very laborious and costly undertaking [11,12], and often requires external financial support, especially in resource-limited countries such as Burundi [9,10]. It is therefore important to look for other cost-effective and sustainable strategies to monitor the impact of MDA campaigns.

In this paper we aim to evaluate whether routine data on intestinal schistosomiasis as determined by direct smear (DS) stool examination and reported by health centres (HC) to the Directorate of National Health Information System (DNHIS), could be used as an approach to monitor the impact of MDA on intestinal schistosomiasis in Burundi.

## Methods

### Functioning of the National Health Information System

The Burundian National Health Information System (NHIS) consists of three levels: the peripheral level (sanitary districts=SD) with HC and district hospitals (DH); the intermediate level (sanitary provinces=SP) with regional hospitals; and the central level (DNHIS) with national and specialised hospitals. Routine data on diseases registered in consultations and laboratory (e.g. malaria, diarrhoea, schistosomiasis) are collected from each HC and reported to the SD, which reports in turn to the SP, and the SP reports to the DNHIS. For hospitals, they report to the SD or to the SP or to the DNHIS, according to the level they belong to. Reporting is done monthly for more than 95% of diseases, including intestinal schistosomiasis.

### Data collection

In 2017, routine data on intestinal schistosomiasis were collected from the DNHS. The data concerned all intestinal schistosomiasis cases as determined by DS and reported by the HC from each SD during the period 2011 to 2015. They were used for this study with the authorisation of the ministry of health (MoH). Data from hospitals were not collected to avoid duplicates as hospitals receive patients referred by HC.

## Data analysis

We described the number of reported cases based on DS detection per year in each SD over a period of 5 years. For the year 2014, with a focus on 2014, where the DS based-incidences at HC level could be compared with the KK-based prevalence in school children.

We analysed temporal trends in intestinal schistosomiasis incident cases for each year in the 11 SD targeted by MDA campaigns (zone of intervention-ZI) with PZQ, and compared them with those in the 34 remaining SD (zone of non-intervention-ZNI), to allow for any general trend in intestinal schistosomiasis, not related to annual MDA by PZQ.

The number of intestinal schistosomiasis cases reported each year were put on a logarithmic scale. The slope should be linear if the incidence remained identical, despite the progressive growth of the population at risk (assumed to be identical for all SD, after the general census of 2008). The effect of MDA campaigns on the annual incidence of intestinal schistosomiasis should manifest itself as a significant change in the slope.

A mixed Negative Binomial regression was performed due to the overdispersion of the data [13,14]. A random effect was added to take into account the existing correlation in the data per district over time. The trends of the number of intestinal schistosomiasis cases reported each year were compared between ZI and ZNI. The respective slopes  $\beta_i$ ,  $i=2012, 2013, 2014, 2015$ , were estimated to compare the trends in ZI and ZNI each year (2012, 2013, 2014 and 2015) to the reference year 2011. A second analysis was performed, for which only one slope  $\beta$  was estimated to study the overall trend during the period of 5 years (from 2011 to 2015). The slope estimation was given for both zones ZI and ZNI. Stata version 12 (Stata Corp. LP, College Station, United States of America) software was used to calculate the slopes with an  $\alpha$  risk error of 5%.

## Results

The routine data obtained by DS showed a decreasing schistosomiasis incidence rate in the majority of the SD in the ZI, and a stable incidence rate in the majority of the SD in the ZNI. However, there were some exceptions in both zones. In the ZI, the incidence rate in the SD of Rumonge remained stable over time, and in the ZNI, the incidence rates in some of the SD decreased, while they increased in others (Table 1).

We were able to compare the data of 2014 (Figure 2) where both districtwide routine surveillance data and school-based mapping data were available. In most SD the low prevalence was confirmed by a low

incidence rate. However, in some SD (e.g. Bururi, Gitega, Musema, Zone Centre) the prevalence rate was zero, while routine surveillance detected some cases. The two districts with the highest prevalences also showed the highest incidence rates, but relatively high incidence rates were also seen in SD with lower prevalences.

Table 2 shows the results of the temporal trends analysis. Both in the ZI and the ZNI, the incidence rate decreased, but this only reached significance in the ZI for 2014 ( $\beta_{2014}=-0.826$ ,  $p=0.010$ ) and 2015 ( $\beta_{2015}=-1.294$ ,  $p<0.001$ ). The overall trend over the five years period (2011 to 2015) showed a highly significant decrease in the ZI ( $\beta=-0.286$ ,  $p<0.001$ ), while no significant trend was observed in the ZNI ( $\beta=-0.087$ ,  $p=0.219$ ). (Figure 1).

## Discussion

MDA campaigns with PZQ are recommended for the control of schistosomiasis [15-17] and constitute the current national strategy for schistosomiasis control in Burundi [18]. The KK test is still the primary diagnostic tool in monitoring the impact of national school based deworming programmes on *S. mansoni* infection [15,17], but it is not available in Burundi as a routine test at PHC level. The only test available for diagnosis of intestinal schistosomiasis in Burundian HC is the DS [18]. We explored whether DS results that are routinely collected at HC level could give an indication of the impact of MDA with praziquantel on *S. mansoni* infection in Burundi as well. We did this by comparing temporal trends in intestinal schistosomiasis as determined by DS in HC of ZI with those in NZI [19,20]. A decreasing trend was observed in the ZI, but not in the ZNI. The decreasing trend in the ZI was in line with the decline in schistosomiasis prevalence from 12.7% in 2007 to 2.2% in 2014 as observed with the gold standard KK test [15] performed in the epidemiological surveys in sentinel sites and in the national mapping [10]. Moreover, comparison of routine surveillance data with school-based mapping data per SD in 2014 showed that for most SD low prevalences based on KK were confirmed by low incidence rates by DS, and that in some districts where the prevalence with KK was zero, routine surveillance still detected some cases.

In contemporary Burundi, schistosomiasis transmission is low to moderate, the health care system is weak and the (national) resources for health care limited. Furthermore, schistosomiasis diagnosis through KK and treatment of positive cases with PZQ is absent in the primary health care setting. Despite these limitations, the current passive routine surveillance system of Burundi appears still be able to monitor the evolution of schistosomiasis in the ZI as well as in the ZNI. Both are equally important in the framework of disease elimination.

Our data hold promise for the use of routine diagnostic data collected at HC level as a cost-effective and sustainable strategy to monitor the impact of MDA campaigns and other schistosomiasis control interventions in Burundi. However, it should be borne in mind that DS, but also KK, have a reduced sensitivity especially in areas of low endemicity, such as Burundi [10]. Highly sensitive diagnostic tools to detect light-intensity infections are pivotal for monitoring progress from control towards elimination [21-

23]. Several studies have now documented the lateral flow immunochromatographic point-of-care (POC) test detecting *Schistosoma* circulating cathodic antigen (CCA) in urine as a valuable alternative to the KK for the diagnosis of *S. mansoni* [24]. It is rapid, user-friendly, and considerably more sensitive than KK especially in areas of low prevalence [25]. While the POC-CCA assay has already shown its value as a mapping and monitoring in national control programmes [10,24], its suitability for integration into the PHC system as a routine test for case management and surveillance/monitoring of intestinal schistosomiasis still needs to be investigated in more detail. Burundi is low endemic for intestinal schistosomiasis and currently aiming for elimination [10]. This, in combination with a relatively well-functioning NHIS system, would provide an ideal setting for such a study.

## Conclusions

The results of this preliminary study suggest that routine surveillance at HC level may be able to monitor the impact of MDA with PZQ on intestinal schistosomiasis in Burundi. However, more sensitive routine diagnostic tests, such as the POC-CCA assay are desirable when moving from control to elimination of schistosomiasis. Further integration of adequate diagnosis and treatment into the routine activities of primary health care facilities is essential for intestinal schistosomiasis to be eliminated in Burundi.

## Abbreviations

CCA: circulating cathodic antigen; DH: district hospital; DNHS: directorate of national health information system; DS: direct smear; HC: health centre; HF: health facility; KK: kato-katz; MDA: mass drug administration; NHIS: national health information system; NTD: neglected tropical diseases; p: p-value; PHC: primary health care; PZQ: praziquantel; SCI: schistosomiasis control initiative; SD: sanitary district; SP: sanitary province; WHO: world health organization, ZI: zone of intervention; ZNI: zone of non-intervention

## Declarations

### Acknowledgements

Authors appreciated also the Director of the Schistosomiasis Control Initiative, Prof Alan Fenwick, for supporting this project. They are also very thankful to the Ministry of Health of Burundi, the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), and the Schistosomiasis Control Initiative (SCI) for the data from the national mapping of 2014 used in this study. They also express their thanks to the staff of the DNIHS who helped to get these data.

### Authors' contributions

PB involved in the acquisition, analysis and interpretation of data for the study and wrote the paper. KP made substantial contributions to the conception of the study, analysed and interpreted data and revised the manuscript critically. GO involved in the conception of the study, analysis and interpretation of data

and revision of the manuscript. MK involved in conception of the methodology, analysis and interpretation of data and revised the manuscript. JPVG: made substantial contributions to the conception of the study, analysis, and interpretation of data, critically revised the manuscript. FN, AN, UB and MN were revised the manuscript. All authors read and approved the final manuscript.

### **Ethics approval and consent to participate**

The research protocol was reviewed and approved by the National Ethics Committee of Burundi in September 2013. Authorisation from the Ministry of Public Health for the study was provided in May 2014.

### **Consent for publication**

Not applicable.

### **Availability of data and materials**

The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

The Schistosomiasis Control Initiative (SCI)/Imperial College and VLIR-UOS funded this study.

### **Author details**

<sup>1</sup>Global Health Institute, Department of Epidemiology and Social Medicine, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium <sup>2</sup>Département des Sciences de la Santé Publique, Direction de la Formation, Institut National de Santé Publique, Bujumbura, Burundi <sup>3</sup>Département de Médecine Communautaire, Faculté de Médecine de Bujumbura, Université du Burundi, Bujumbura, Burundi <sup>4</sup>Département des Sciences de la Santé Publique, Institut Universitaire des Sciences de la Santé et de Développement Communautaire, Bujumbura, Burundi <sup>5</sup>Faculté de Médecine, Université de Ngozi, Ngozi, Burundi <sup>6</sup>Medical Helminthology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium <sup>7</sup>Section of Infectious Diseases, VU University in Amsterdam, Amsterdam, The Netherlands <sup>8</sup>Global Health Consultant, London United Kingdom <sup>9</sup>Biostatistics and Epidemiology Unit, Biomedical Department, Institute of Tropical Medicine, Antwerp, Belgium <sup>10</sup>Département de Médecine Interne, Faculté de Médecine de Bujumbura, Université du Burundi, Bujumbura, Burundi <sup>11</sup>Bureau de la Municipalité Sanitaire de Bujumbura, Ministère de la Santé Publique et de la Lutte contre le Sida, Bujumbura, Burundi

# References

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. *Lancet* 2006; 368:1106-18.
2. Raso G, Vounatsou P, McManus DP, N'Goran EK, Utzinger J. A Bayesian approach to estimate the age-specific prevalence of *Schistosoma mansoni* and implications for schistosomiasis control. *Int J Parasitol* 2007; 37:1491-500.
3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 2006; 6:411-25.
4. Clements AC, Brooker S, Nyandindi U, Fenwick A, Blair L. Bayesian spatial analysis of a national urinary schistosomiasis questionnaire to assist geographic targeting of schistosomiasis control in Tanzania, East Africa. *Int J Parasitol* 2008; 38:401-15.
5. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. *Acta Trop* 2000; 77:41-51.
6. Tchouanguem HN, Fouelifack FY, Keugoung B, Fouelifa LD, Moyou RS. [Current status of schistosomiasis in Santchou health area, (Santchou Health District, Cameroon western region)]. *Pan Afr Med J* 2016; 24:137.
7. F. de Bève. Bilharziose en Ruanda-Urundi et spécialement à Usumbura. *Annales de la Société Belge de Médecine Tropicale* 1935; XV:3-18.
8. Neujan G. Le parasitisme intestinal chez les indigènes des Hauts Plateaux(environs de Kitega). *Annale de la Société Belge de Médecine Tropicale* 1937; XVII:343-9.
9. Ndayishimiye O, Ortu G, Soares Magalhaes RJ, Clements A, Willems J, Whitton J et al. Control of neglected tropical diseases in Burundi: partnerships, achievements, challenges, and lessons learned after four years of programme implementation. *PLoS Negl Trop Dis* 2014; 8:e2684.
10. Ortu G, Ndayishimiye O, Clements M, Kayugi D, Campbell CH, Jr., Lamine MS et al. Countrywide Reassessment of *Schistosoma mansoni* Infection in Burundi Using a Urine-Circulating Cathodic Antigen Rapid Test: Informing the National Control Program. *Am J Trop Med Hyg* 2017.
11. Sousa-Figueiredo JC, Stanton MC, Katokele S, Arinaitwe M, Adriko M, Balfour L et al. Mapping of Schistosomiasis and Soil-Transmitted Helminths in Namibia: The First Large-Scale Protocol to Formally Include Rapid Diagnostic Tests. *PLoS Negl Trop Dis* 2015; 9:e0003831.
12. Worrell CM, Bartoces M, Karanja DM, Ochola EA, Matete DO, Mwinzi PN et al. Cost analysis of tests for the detection of *Schistosoma mansoni* infection in children in western Kenya. *Am J Trop Med Hyg* 2015; 92:1233-39.
13. Gardner W, Mulvey EP, Shaw EC: Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. *Psychol Bull* 1995; 118:392-404.
14. Verbeke G, Molenberghs G. *Linear Mixed Models for Longitudinal Data*. Springer, New York, 2000.
15. WHO. The control of schistosomiasis. *World Health Organ Tech Rep Ser*. 1993; 830:1-86.

16. WHO. Schistosomiasis and soil-transmitted helminthiasis: prevention and control. World Health Organ Tech Rep Ser. 2004; 912:29-55.
17. WHO. Schistosomiasis and soil-transmitted helminthiasis: prevention and control. World Health Organ Tech Rep Ser. 2002; 912:25-50.
18. Bizimana P, Polman K, Van Geertruyden JP, Nsabiyumva F, Ngenzeuhoro C, Muhimpundu E et al. Capacity gaps in health facilities for case management of intestinal schistosomiasis and soil-transmitted helminthiasis in Burundi. *Infect Dis Poverty* 2018; 7: 66.
19. Engels D, Nahimana S, Gryseels B. Comparison of the direct faecal smear and two thick smear techniques for the diagnosis of intestinal parasitic infections. *Trans R Soc Trop Med Hyg* 1996; 90:523-25.
20. WHO. Basic Laboratory methods in medical parasitology. Geneva, World Health Organization 1991:1-69.
21. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuenté LA, Garba A et al. Time to set the agenda for schistosomiasis elimination. *Acta Trop* 2013; 128:423-40.
22. Adriko M, Standley CJ, Tinkitina B, Tukahebwa EM, Fenwick A, Fleming FM et al. Evaluation of circulating cathodic antigen (CCA) urine-cassette assay as a survey tool for *Schistosoma mansoni* in different transmission settings within Bugiri District, Uganda. *Acta Trop* 2014; 136:50-7.
23. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, Webster JP. Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for *Schistosoma mansoni* diagnosis pre- and post-repeated-praziquantel treatment. *PLoS Negl Trop Dis* 2014; 8:e3139.
24. Sousa-Figueiredo JC, Betson M, Kabatereine NB, Stothard JR. The urine circulating cathodic antigen (CCA) dipstick: a valid substitute for microscopy for mapping and point-of-care diagnosis of intestinal schistosomiasis. *PLoS Negl Trop Dis* 2013; 7:e2008.
25. Kittur N, Castleman JD, Campbell CH, King CH, Colley DG. Comparison of *Schistosoma mansoni* Prevalence and Intensity of Infection, as Determined by the Circulating Cathodic Antigen Urine Assay or by the Kato-Katz Fecal Assay: A Systematic Review. *Am J Trop Med Hyg* 2016; 94:605-10.

## Tables

**Table 1** Number of intestinal schistosomiasis cases per SD and per year as determined by direct smear at HC level in Burundi.

SD name	ZONE	2011	2012	2013	2014	2015
Bubanza	ZNI	99	78	36	143	63
Rwibaga	ZNI	103	14	0	2	6
Bururi	ZNI	8	1	2	14	22
Matana	ZNI	32	9	21	19	20
Cankuzo	ZNI	10	1	0	2	0
Murore	ZNI	1	18	4	0	0
Mabayi	ZNI	64	74	38	30	53
Gitega	ZNI	27	17	24	55	31
Kibuye	ZNI	0	1	5	1	2
Mutaho	ZNI	13	2	3	6	1
Ryansoro	ZNI	4	0	3	4	2
Buhiga	ZNI	0	2	0	2	0
Nyabikere	ZNI	0	4	0	0	1
Kayanza	ZNI	6	6	8	7	69
Musema	ZNI	5	7	2	31	8
Gahombo	ZNI	30	25	18	6	15
Mukenke	ZNI	13	4	4	5	0
Vumbi	ZNI	27	26	26	26	1
Makamba	ZNI	238	267	249	270	195
Muramvya	ZNI	0	19	3	103	2
Kiganda	ZNI	0	5	6	3	15
Muyinga	ZNI	28	17	8	19	31
Gashoho	ZNI	38	9	1	0	0
Giteranyi	ZNI	0	22	152	7	12
Kibumbu	ZNI	10	2	40	4	19
Fota	ZNI	0	0	0	0	0
Ngozi	ZNI	5	1	0	32	0
Kiremba	ZNI	9	97	3	34	0
Buye	ZNI	0	0	0	0	0
Rutana	ZNI	12	30	15	5	2
Gihofi	ZNI	15	68	72	16	13
Butezi	ZNI	9	4	0	5	2
Kinyinya	ZNI	69	25	99	125	103
Ruyigi	ZNI	1	1	6	2	1
Mpanda	ZI	585	397	307	121	118
Zone Nord	ZI	493	483	215	118	50
Zone Centre	ZI	504	9	70	22	36
Zone Sud	ZI	145	24	23	11	39
Kabezi	ZI	115	47	56	174	82
Isale	ZI	210	156	71	346	53
Rumonge	ZI	189	136	374	213	351
Cibitoke	ZI	883	996	901	296	169
Kirundo	ZI	10	21	9	12	3
Busoni	ZI	23	23	103	15	4
Nyanza-Lac	ZI	247	315	255	263	149


SD: sanitary district ; ZI : zone of intervention; ZNI : zone of non-intervention; HC: health centre

**Table 2** Analysis of annual trends in intestinal schistosomiasis cases in zones in Burundi that were targeted for MDA with PZQ (ZI) and zones that were not (ZNI).

Year	Zone	SD (nr)	Intestinal schistosomiasis cases (nr)	$\beta$	95% IC	p-value
2011	ZI	11	3404	1	-	-
	ZNI	34	876	1	-	-
2012	ZI	11	2607	-0.563	[-1.180;0.054]	0.074
	ZNI	34	856	-0.157	[-0.757;0.443]	0.607
2013	ZI	11	2384	-0.521	[-1.140;0.097]	0.098
	ZNI	34	848	-0.324	[-0.940;0.292]	0.302
2014	ZI	11	1581	-0.826	[-1.454;-0.198]	0.010*
	ZNI	34	978	-0.055	[-0.663;0.553]	0.859
2015	ZI	11	1054	-1.294	[-1.908;-0.680]	< 0.001*
	ZNI	34	689	-0.508	[-1.121;0.105]	0.104
2011-2015	ZI	11	-	-0.286	[-0.429;-0.144]	<0.001*
	ZNI	34	-	-0.087	[-0.227;0.052]	0.219


\*: significant; SD: Sanitary district; nr: number; ZI: Zone of intervention, targeted for MDA with PZQ; ZNI: Zone of non-intervention, not targeted for MDA with PZQ

## Figures



**Figure 1**

Temporal trends in schistosomiasis in the ZI and in the ZNI ZI: zone of intervention, targeted for MDA with PZQ; ZNI: zone of non-intervention, not targeted for MDA with PZQ



**Figure 2**

Prevalence (%) by KK in school children and incidence (%) by DS at HC level in 2014, Burundi KK: kato-katz test; %: percentage; DS: direct smear; HC: health centre